risperidone has been researched along with Atrophy in 8 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cerebral cortical gray was examined volumetrically in 19 patients with schizophrenia before and following 28 days of treatment with two SGAs (risperidone and ziprasidone; n = 13) or a FGA (haloperidol; n = 6)." | 5.11 | Cerebral cortical gray expansion associated with two second-generation antipsychotics. ( Christensen, JD; Garver, DL; Holcomb, JA, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tendilla-Beltrán, H | 1 |
| Meneses-Prado, S | 1 |
| Vázquez-Roque, RA | 1 |
| Tapia-Rodríguez, M | 1 |
| Vázquez-Hernández, AJ | 1 |
| Coatl-Cuaya, H | 1 |
| Martín-Hernández, D | 1 |
| MacDowell, KS | 1 |
| Garcés-Ramírez, L | 1 |
| Leza, JC | 1 |
| Flores, G | 1 |
| Thomas Antérion, C | 1 |
| Convers, P | 1 |
| Desmales, S | 1 |
| Borg, C | 1 |
| Laurent, B | 1 |
| Campbell, JJ | 1 |
| Ngo, G | 1 |
| Takahashi, T | 1 |
| Wood, SJ | 1 |
| Yung, AR | 1 |
| Soulsby, B | 1 |
| McGorry, PD | 1 |
| Suzuki, M | 1 |
| Kawasaki, Y | 1 |
| Phillips, LJ | 1 |
| Velakoulis, D | 1 |
| Pantelis, C | 1 |
| Duggal, H | 1 |
| Singh, I | 1 |
| Garver, DL | 1 |
| Holcomb, JA | 1 |
| Christensen, JD | 1 |
| Molina, V | 1 |
| Reig, S | 1 |
| Sanz, J | 1 |
| Palomo, T | 1 |
| Benito, C | 1 |
| Sánchez, J | 1 |
| Sarramea, F | 1 |
| Pascau, J | 1 |
| Desco, M | 1 |
| Curtis, RC | 1 |
| Resch, DS | 1 |
2 trials available for risperidone and Atrophy
| Article | Year |
|---|---|
Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Atrophy; Bipolar Disorder; Cognitive Behavioral Therapy; Co | 2009 |
Cerebral cortical gray expansion associated with two second-generation antipsychotics.
Topics: Adult; Antipsychotic Agents; Atrophy; Cerebral Cortex; Cognition Disorders; Female; Follow-Up Studie | 2005 |
6 other studies available for risperidone and Atrophy
| Article | Year |
|---|---|
Risperidone Ameliorates Prefrontal Cortex Neural Atrophy and Oxidative/Nitrosative Stress in Brain and Peripheral Blood of Rats with Neonatal Ventral Hippocampus Lesion.
Topics: Animals; Antipsychotic Agents; Atrophy; Dendritic Spines; Hippocampus; Male; Nitrosative Stress; Oxi | 2019 |
An odd manifestation of the Capgras syndrome: loss of familiarity even with the sexual partner.
Topics: Aged; Amnesia; Antipsychotic Agents; Atrophy; Brain; Capgras Syndrome; Donepezil; Hallucinations; Hu | 2008 |
Risperidone treatment of complex hallucinations in a patient with posterior cortical atrophy.
Topics: Atrophy; Brain Diseases; Cerebral Cortex; Dopamine Antagonists; Hallucinations; Risperidone | 2008 |
Delusional parasitosis as a presenting feature of dementia.
Topics: Aged; Animals; Antipsychotic Agents; Atrophy; Brain; Delusions; Dementia; Diagnosis, Differential; F | 2010 |
Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia.
Topics: Adult; Antipsychotic Agents; Atrophy; Brain; Chronic Disease; Clozapine; Female; Follow-Up Studies; | 2005 |
Case of pick's central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone.
Topics: Adult; Antipsychotic Agents; Atrophy; Brain; Cognition Disorders; Female; Humans; Magnetic Resonance | 2000 |